Naxos Disease — Comprehensive Research Report

1. Disease Information

Overview: Naxos disease (Naxos syndrome; also called cardiocutaneous syndrome) is a rare, autosomal recessive disorder defined by a triad: woolly hair, diffuse non-epidermolytic palmoplantar keratoderma (PPK), and arrhythmogenic right ventricular cardiomyopathy (ARVC). It is the prototype "cardiocutaneous syndrome" and was the first ARVC subtype for which the causal gene was identified, establishing desmosomal dysfunction as a mechanism of arrhythmogenic cardiomyopathy more broadly (McKoy et al., Lancet 2000, PMID: 10902626). It was first clinically described by Protonotarios and colleagues in 1986 in nine patients from four families on the Greek island of Naxos ("Cardiac abnormalities in familial palmoplantar keratosis," Br Heart J 1986;56:321-6), from which the eponym derives.

Key identifiers: - OMIM: #601214 (Naxos disease, NXD); gene locus 173325 (JUP, junction plakoglobin) - Orphanet: ORPHA:34217 - MONDO: MONDO:0009782 - MeSH/related: indexed under "Arrhythmogenic Right Ventricular Dysplasia" and "Hair Diseases, Woolly Hair" cross-terms; GARD/GTR record C1832600 - ICD-10: typically coded via Q84.8 (other specified congenital malformations of integument) plus I42.8/I42.9 for the cardiomyopathy component, since no dedicated ICD-10 code exists for the syndrome as a unit - Related/allelic disorder: Carvajal syndrome (a DSP/desmoplakin-mutant variant with predominant left-ventricular/dilated cardiomyopathy) is often described as "the Naxos disease variant" and grouped with it under the broader keratoderma-with-woolly-hair* cardiocutaneous spectrum.

Evidence base: Almost all data derive from aggregated disease-level resources — case series and pedigree studies from the founder Greek-island population (Naxos, other Cyclades), plus subsequently identified families in Turkey, Israel, Saudi Arabia, India, Bangladesh, Argentina, Ecuador, and French-Canadian populations — rather than large EHR-based cohorts, reflecting its rarity. Sources: Orphanet Journal of Rare Diseases review, PMID: 16722579; JACC: Advances review 2024 (PMC11773020).

2. Etiology

Causal factor: Naxos disease is a monogenic, autosomal recessive disorder. The classic and founder mutation is a homozygous 2-base-pair deletion (2157del2, historically also annotated as c.2037-2038delTG) in exon 14 of JUP (junction plakoglobin, 17q21.2), causing a frameshift, loss of the last 56 C-terminal residues (including part of the 13th armadillo repeat), and truncation of the plakoglobin protein (McKoy et al. 2000, PMID: 10902626; gene mapped to 17q21 by Coonar et al., Circulation 1998, PMID: 9610534 [linkage mapping paper]).

• Genetic risk factor: Biallelic (homozygous, or compound heterozygous) loss-of-function JUP variants. Heterozygous carriers are asymptomatic (recessive), though isolated dominant JUP missense mutations have separately been reported to cause a milder, cardiac-only ARVC phenotype without the cutaneous features (PMID: 17924338) — an important genotype-phenotype distinction.
• Allelic/genetically related disorder — Carvajal syndrome: biallelic loss-of-function mutations in DSP (desmoplakin, 6p24.3), which binds plakoglobin at the desmosomal plaque, cause an overlapping but left-ventricle-predominant, earlier-onset dilated cardiomyopathy with the same cutaneous triad (Norgett et al. 2000, PMID: 11063735; Rampazzo et al. 2002; Protonotarios & Tsatsopoulou 2004, PMID: 15210133).
• Founder effect: The homozygous JUP 2157del2 mutation is a founder mutation traced to the Aegean island population, with carrier frequency reported up to ~5% in the Naxos population and disease prevalence approaching 1:1000 on the island — among the highest reported prevalences for any severe recessive cardiomyopathy (Protonotarios & Tsatsopoulou, Orphanet J Rare Dis 2018, PMID not directly retrieved but summarized in PMC review chain; see also PMID: 16722579).
• Consanguinity: Historically relevant given the isolated island population structure; non-Greek cases (Turkey, Saudi Arabia, India, Israel) similarly often arise in consanguineous or genetically isolated communities. A separate Arab family was shown to have Naxos-like disease not due to the Pk2157del2 mutation, indicating locus heterogeneity even within apparently classic phenotypes (PMID: 15494820).
• Environmental/modifying factors: Not causal, but physical exertion/endurance exercise is a well-documented disease-modifying and arrhythmia-triggering factor — it accelerates myocyte detachment under mechanical stress, worsens right ventricular remodeling, and increases risk of ventricular arrhythmia and sudden death (supported mechanistically in murine Jup+/− models, where swim training accelerated RV dilation — PMID: 32670084 review). This mirrors general ARVC genotype-agnostic exercise risk data.
• Protective factors: No genetic or environmental protective factors are established. There is no known modifier allele that attenuates penetrance — cardiac penetrance approaches 100% by adulthood in JUP-homozygous individuals.
• Gene-environment interaction: Mechanical/hemodynamic stress (exercise) interacting with a structurally weakened desmosome-intermediate filament network is the central G×E paradigm: the disrupted cell-adhesion complex cannot withstand repetitive shear stress in the thin-walled right ventricle, precipitating myocyte death, inflammation and fibrofatty replacement preferentially in mechanically stressed regions.

3. Phenotypes

The triad has a characteristic temporal sequence — cutaneous/hair features present from birth/infancy, cardiac disease emerges later — which is itself diagnostically important.

Quality of life impact: The dermatologic features (woolly hair texture, thickened/fissured palmoplantar skin) can cause cosmetic distress and mechanical discomfort (fissuring, pain on ambulation) from infancy, while the cardiac disease drives the major morbidity/mortality burden — activity restriction, ICD-related psychological impact, risk of sudden death, and progression to heart failure/transplantation in advanced cases. No disease-specific validated QoL instrument was identified in the literature searched; ARVC-general QoL data (activity limitation, ICD shock anxiety) are presumed to apply.

4. Genetic/Molecular Information

Causal gene: JUP (Junction Plakoglobin, also known as γ-catenin), HGNC:6207, chromosome 17q21.2, OMIM 173325. Encodes plakoglobin, a member of the armadillo-repeat protein family shared between desmosomes and adherens junctions*.

• Founder pathogenic variant: homozygous 2-bp deletion, 2157del2 (legacy nomenclature), historically also cited as c.2036-2037delTG / c.2037-2038delTG depending on transcript numbering — causes a frameshift and premature stop codon, truncating the C-terminal 56 amino acids of the 13th armadillo repeat domain (McKoy 2000, PMID: 10902626). This is a clear loss-of-function allele (confirmed functionally in knock-in mouse models via nonsense-mediated decay rescue experiments — PMC7327121 review).
• Variant classification: Pathogenic per ClinVar/ACMG (frameshift, null variant in a gene where LOF is an established disease mechanism, segregates with recessive phenotype in multiple families, absent/extremely rare in population databases such as gnomAD given founder-population enrichment only).
• Locus heterogeneity: A separate Arab-family case of clinically classic Naxos disease was shown not to be caused by the 2157del2 mutation and JUP was formally excluded by linkage, indicating genetic heterogeneity — additional causal loci exist for the same phenotype (PMID: 15494820).
• Allelic dominant variant: A distinct dominant JUP missense mutation causes non-syndromic ARVC (cardiac-only, no cutaneous phenotype) — illustrating that zygosity/variant type, not just gene identity, determines phenotype severity and tissue distribution (PMID: 17924338).
• Related gene (Carvajal syndrome): DSP (Desmoplakin), HGNC:3052, 6p24.3, OMIM *125647. Biallelic DSP truncating variants (e.g., a variant disrupting the intermediate-filament-binding domain, reported in Ecuadorian families) cause the DSP-associated cardiocutaneous variant with predominant/early left-ventricular dilated cardiomyopathy (Norgett 2000 PMID: 11063735; Carvajal-variant genotype-outcome study PMC11924745).
• Functional consequence: Loss (or severe truncation) of plakoglobin protein disrupts desmosomal plaque assembly, weakening cell-cell adhesion at intercalated discs (heart) and at keratinocyte desmosomes (skin/hair follicle). Because plakoglobin is a dual adherens-junction/desmosome and Wnt-signaling component, its loss also de-represses nuclear signaling (see Mechanism, below).
• Population frequency: Homozygotes are essentially confined to founder-effect populations (Naxos and other Aegean islands); the pathogenic allele is at very low frequency genome-wide (not a common gnomAD variant) but locally enriched (~5% Naxos carrier frequency).
• Somatic vs. germline: Purely germline (constitutional) — no somatic mosaicism or oncologic relevance reported.
• Epigenetics: No disease-specific DNA methylation/histone-modification studies were identified specific to Naxos disease; broader ARVC epigenomic studies are limited and non-specific to JUP.
• Chromosomal abnormalities: None — Naxos disease is a single-gene, small-indel disorder, not a copy-number/structural chromosomal disease.
• Modifier genes: None formally established for Naxos disease specifically; in the broader ARVC/desmosomal-cardiomyopathy literature, digenic/oligogenic modifier effects (e.g., additional desmosomal gene variants) are increasingly recognized as influencing severity, but this is not yet mapped for JUP-Naxos cohorts specifically.

Suggested ontology terms: Gene — hgnc:6207 (JUP); protein — UniProt P14923 (plakoglobin/γ-catenin); GO molecular function GO:0005198 (structural molecule activity) / GO:0045296 (cadherin binding); GO cellular component GO:0030057 (desmosome), GO:0005913 (cell-cell adherens junction), GO:0014704 (intercalated disc).

5. Environmental Information

Naxos disease is fundamentally a monogenic disorder, so classic "environmental etiology" does not apply to causation. Environmental factors instead act as disease modifiers/triggers:

• Physical exertion: The single best-documented environmental modifier. Endurance/competitive exercise increases mechanical stress on a desmosomally weakened right ventricle, accelerating myocyte loss, fibrofatty replacement, and arrhythmic risk — consistent with general ARVC exercise-restriction guidance and with murine swim-training data in Jup+/− mice (PMC7327121).
• Occupational/mechanical friction: Repetitive mechanical stress on palms/soles (e.g., barefoot walking, manual labor from childhood) is proposed to explain the site-specific severity and appearance timing of the keratoderma (emerging as infants begin weight-bearing/grasping), paralleling the "mechanical stress unmasks weak adhesion" theme seen in the heart.
• Toxins/pollutants: No specific toxin, chemical, or occupational exposure has been implicated.
• Lifestyle factors: Beyond exercise, no diet, smoking, or alcohol associations are documented specific to Naxos disease; standard cardiovascular risk-factor management is presumably still relevant for concurrent cardiovascular health but is not disease-modifying in a specific mechanistic sense.
• Infectious agents: None implicated in Naxos disease etiology. (Myocardial inflammation/myocarditis-like infiltrates are part of the downstream pathophysiology — see Mechanism — but this is sterile/mechanically triggered inflammation, not an infectious trigger.)

6. Mechanism / Pathophysiology

Causal chain (trigger → clinical manifestation):

1. Molecular lesion: Homozygous JUP frameshift/truncation → loss of functional, full-length plakoglobin protein (or severely truncated, non-functional protein) (PMID: 10902626).
2. Desmosomal/adherens-junction assembly failure: Plakoglobin is a core structural linker of the desmosomal plaque (binding desmosomal cadherins — desmoglein/desmocollin — to intermediate filaments via desmoplakin) and of adherens junctions (binding classical cadherins to the actin cytoskeleton). Its loss destabilizes intercalated discs in cardiomyocytes and desmosomes in epidermal keratinocytes/hair follicle keratinocytes.
3. Mechanical failure under stress: Because desmosomes and adherens junctions provide the mechanical "glue" resisting shear stress, the weakened junctional complex fails preferentially under repetitive mechanical load — the thin-walled, high-wall-stress right ventricle in the heart, and the friction-exposed palms/soles and hair shaft in the skin. This produces progressive myocyte detachment, cell death, and myocardial atrophy, replaced by fibrofatty tissue (the histologic hallmark of ARVC).
4. Electrical remodeling / arrhythmogenesis: Structural intercalated-disc disruption is accompanied by mislocalization/downregulation of connexin-43 gap junctions, slowing and heterogenizing electrical conduction; the fibrofatty replacement itself creates anatomic re-entry substrate. Together these generate ventricular tachyarrhythmia (typically LBBB-morphology VT arising from right ventricular substrate) and risk of sudden cardiac death.
5. Signaling dysregulation (Wnt/GSK3β axis): Plakoglobin is a paralog of β-catenin and, when displaced from the desmosome, can translocate to the nucleus, competing with β-catenin and suppressing canonical Wnt/β-catenin signaling. This shift is mechanistically linked to adipogenic transdifferentiation of cardiac progenitor/myocardial cells, contributing to the fibrofatty phenotype. Glycogen synthase kinase-3β (GSK3β) was identified as a central convergent node: in two independent murine desmosomal-mutant models (plakoglobin-Naxos-mutant transgenic mice and Dsg2 knock-in mice), pharmacologic GSK3β inhibition rescued myocyte injury, fibrosis, inflammation, and arrhythmia, while constitutive GSK3β activation worsened disease — establishing GSK3β as a druggable convergence point downstream of desmosomal loss (Chelko, Asimaki, Judge et al., JCI Insight 2016, PMID: 27170944). This has since progressed to an active clinical trial of GSK3 inhibition for arrhythmogenic cardiomyopathy (ClinicalTrials.gov NCT06174220).
6. Inflammatory amplification: Myocyte injury triggers sterile inflammatory infiltration (macrophage/lymphocytic), which further injures myocardium and promotes fibrosis — a "hit-and-run" myocarditis-like component increasingly recognized in desmosomal ARVC pathogenesis (related mechanistic work: CCR2+ macrophage-driven injury in murine ACM models).
7. Skin/hair phenotype mechanism: The same desmosomal weakening in the epidermis and hair-follicle keratinocytes underlies the non-epidermolytic palmoplantar keratoderma (compensatory hyperkeratosis in response to chronic mechanical/adhesive stress) and woolly hair (structurally abnormal hair shaft formation due to follicular desmosome dysfunction).

Cell types involved: cardiomyocytes (CL:0000746), cardiac fibroblasts (CL:0000057) and myofibroblasts, epicardial/subepicardial adipocytes (CL:0000136), infiltrating macrophages (CL:0000235), epidermal keratinocytes (CL:0000312), hair follicle keratinocytes/trichocytes.

Suggested GO terms: GO:0030057 (desmosome), GO:0005911 (cell-cell junction), GO:0016055 (Wnt signaling pathway), GO:0060071 (Wnt-Frizzled-LRP5/6 complex-related regulation), GO:0007507 (heart development), GO:0055010 (ventricular cardiac muscle tissue morphogenesis), GO:0070268 (cornification, for the keratoderma arm), GO:0042733 (embryonic digit morphogenesis — n/a), GO:0006915 (apoptotic process, for myocyte death).

Suggested UBERON/anatomical terms: UBERON:0002080 (heart right ventricle), UBERON:0014704-type intercalated disc terms if modeled, UBERON:0001003 (skin epidermis), UBERON:0002073 (palm skin) / sole skin, UBERON:0002073, hair follicle UBERON:0002073-adjacent structures.

Fit to dismech mechanism-module framework: This disorder is a strong candidate conformer to relevant dismech mechanism modules — notably cardiomyopathy_maladaptive_remodeling (structural/contractile arm) and cardiac_ion_channel_repolarization/arrhythmogenic-substrate concepts for the ventricular tachyarrhythmia arm, plus potentially a bespoke desmosomal cell-adhesion node given its status as the founding cause of the broader arrhythmogenic-cardiomyopathy disease class.

7. Anatomical Structures Affected

Organ level: - Primary: Heart — predominantly right ventricle (classic Naxos/JUP disease); skin (palms and soles); hair/hair follicles (scalp). - Secondary/complication-driven: Left ventricle (in advanced/biventricular disease and especially in the DSP-Carvajal variant), systemic venous system/liver (right heart failure congestion in end-stage disease). - Body systems: Cardiovascular system (primary), integumentary system (primary), and secondarily the conduction system (arrhythmia).

Tissue/cell level: - Cardiac muscle tissue — ventricular myocardium, intercalated discs, subepicardial/epicardial adipose and fibrous tissue (fibrofatty replacement). - Epidermis — stratum corneum thickening (keratoderma); hair shaft/follicle keratinocytes (woolly hair). - Cell populations: cardiomyocytes, cardiac fibroblasts/myofibroblasts, adipocytes, macrophages/lymphocytes (inflammatory infiltrate), keratinocytes.

Subcellular level: - Desmosomes and adherens junctions at the intercalated disc (GO:0014704) and at keratinocyte cell-cell borders (GO:0030057, GO:0005913). - Gap junctions (connexin-43, GO:0005921) — secondarily mislocalized. - Nucleus — site of aberrant plakoglobin translocation and Wnt-pathway interference.

Localization/laterality: Right ventricle is classically and preferentially affected early (bilateral/global cutaneous involvement of palms and soles; scalp hair diffusely woolly, not focal). Cardiac disease frequently progresses to biventricular involvement over the disease course (>50% by 10-year follow-up per Protonotarios/Tsatsopoulou natural-history data, PMID: 16722579); the DSP-Carvajal variant is distinguished by predominant/early left ventricular involvement.

8. Temporal Development

• Onset: Cutaneous features (woolly hair) are present at or shortly after birth; palmoplantar keratoderma emerges in the first year of life as the hands/feet begin bearing mechanical/functional load. Cardiac disease is occult in childhood (concealed ECG-only abnormalities may be detectable), becoming clinically overt in adolescence to young adulthood, with roughly one-third of patients symptomatic before age 30.
• Onset pattern: Cutaneous features — congenital/insidious. Cardiac disease — insidious progression through a concealed phase, punctuated by acute arrhythmic events (syncope, VT, or sudden death as first presentation in some patients).
• Disease stages (classic three-phase ARVC natural history model, directly documented for Naxos disease):
• Concealed phase: subtle ECG repolarization/depolarization abnormalities (e.g., T-wave inversion in right precordial leads, epsilon waves), minimal or no structural changes, patient largely asymptomatic; sudden death can rarely occur even in this phase during exertion.
• Overt/arrhythmic phase: symptomatic ventricular arrhythmias (typically LBBB-morphology sustained VT), syncope, palpitations; progressive right (and often biventricular) structural/functional deterioration.
• Heart failure/end-stage phase: right (or biventricular) pump failure, congestive symptoms, potential need for transplantation.
• Progression rate: Variable but generally progressive over years to decades; biventricular extension in >50% of patients over 10 years of follow-up (PMID: 16722579). The Carvajal/DSP variant progresses faster and earlier, with heart failure in ~50% of patients and death frequently in childhood/adolescence.
• Course pattern: Progressive structural disease with a superimposed episodic arrhythmic component (VT episodes are paroxysmal against a background of progressive myocardial replacement).
• Duration: Chronic, lifelong — no spontaneous remission of the underlying structural disease; arrhythmic episodes may remit/recur unpredictably. Disease-modifying therapy does not reverse fibrofatty replacement.
• Critical periods: Adolescence and young adulthood represent the critical window during which concealed disease becomes overt and sudden death risk sharply rises — this is the rationale for cardiac screening beginning in the pre-teen/teen years in known JUP-homozygous family members, and for exercise-restriction counseling initiated as early as possible once genotype/phenotype risk is established.

9. Inheritance and Population

Epidemiology: - Prevalence: Estimated ~1:1000 on the island of Naxos and neighboring Aegean islands — an extraordinarily high prevalence for a lethal recessive cardiomyopathy, attributable to founder effect and historical geographic/reproductive isolation. - Carrier frequency: Up to ~5% heterozygous carriers in the Naxos population. - Global rarity: Outside the founder population, Naxos disease is extremely rare, with case reports/small series from Turkey, Israel, Saudi Arabia, India, Bangladesh, Argentina, Ecuador (Carvajal variant), and French-Canadian kindreds.

Inheritance pattern: Autosomal recessive. Both parents of an affected individual are obligate heterozygous carriers (typically asymptomatic).

Penetrance: Cardiac phenotype shows very high (~100%) penetrance by adulthood in homozygotes, though the timing of overt cardiac manifestation is variable (concealed-phase duration differs between individuals). Cutaneous features are essentially fully penetrant from infancy.

Expressivity: Variable in cardiac disease severity/progression rate and in age at first arrhythmic event, even among relatives sharing the identical homozygous genotype — implying modifier effects (genetic and/or environmental, especially exercise exposure) not yet fully characterized.

Genetic anticipation: Not reported/expected — this is a small-indel loss-of-function disorder, not a repeat-expansion disease.

Germline mosaicism: Not specifically documented for JUP-Naxos disease in the literature reviewed.

Founder effect: Well-established — the 2157del2 JUP mutation is the paradigmatic founder mutation for the Aegean/Naxos population; a distinct, non-JUP cause was documented in an unrelated Arab family with a phenocopy (PMID: 15494820), underscoring that "Naxos disease" is a clinical/phenotypic diagnosis with genetic heterogeneity, while "JUP-related Naxos disease" is the genetically defined founder-mutation entity.

Consanguinity: Plausibly relevant historically in the isolated island population and in reported non-Greek kindreds, though formal consanguinity rates were not quantified in the sources reviewed.

Population demographics: - Geographic distribution: Endemic focus on Naxos and other Cyclades/Aegean islands (Greece); sporadic kindreds reported in Turkey, Israel, Saudi Arabia, India, Bangladesh, Argentina, Ecuador, and French-Canadian populations. - Sex ratio: No strong sex predilection is reported for an autosomal recessive disorder; ARVC generally (non-Naxos) shows some male predominance in symptomatic presentation, but Naxos-specific sex-ratio data were not identified in this search. - Age distribution: Skin findings from birth/infancy; cardiac diagnosis clusters in adolescence/young adulthood, consistent with the concealed-to-overt phase transition.

10. Diagnostics

Clinical recognition: The triad (woolly hair + PPK + ARVC) in a patient (especially from an endemic population) is highly suggestive and typically prompts genetic confirmation.

Clinical/cardiac tests: - ECG: T-wave inversion in right precordial leads (V1–V3), epsilon waves, prolonged QRS/terminal activation duration, and ventricular arrhythmia of left bundle branch block (LBBB) morphology (indicating right ventricular origin). - Echocardiography: Right ventricular dilation, regional wall-motion abnormality/akinesia/dyskinesia, reduced RV ejection fraction; may progress to involve the left ventricle. - Cardiac MRI: Assessment of RV (and LV) structure/function, wall-motion abnormalities, and myocardial fibrofatty infiltration (late gadolinium enhancement) — a cornerstone modality per the 2010/2023 Task Force imaging criteria. - Signal-averaged ECG (SAECG): Detects late potentials reflecting delayed, fragmented conduction. - Ambulatory/Holter monitoring and exercise testing: To detect ventricular ectopy/VT burden, often exercise-induced. - Electrophysiology study: For arrhythmia characterization and risk stratification in selected patients. - Endomyocardial biopsy / histopathology (when performed, or at autopsy): Fibrofatty replacement of right ventricular myocardium, myocyte loss — the classic pathologic hallmark; reduced/altered immunohistochemical signal for plakoglobin at the intercalated disc has been proposed as a relatively specific diagnostic biomarker for desmosomal ARVC (Asimaki et al. immunohistochemistry work, broader ARVC literature). - Diagnostic framework: The disease is diagnosed under the general ARVC Task Force Criteria (originally 1994, revised 2010 International Task Force Criteria, further refined by the 2023 European Task Force Criteria for Arrhythmogenic Cardiomyopathy), combining major/minor criteria across structural imaging, tissue characterization, repolarization abnormalities, depolarization/conduction abnormalities, arrhythmias, and family history/genetics — with a positive family history of a confirmed pathogenic desmosomal variant, or presence of the cutaneous phenotype, constituting a major criterion category. In Naxos disease specifically, the presence of the pathognomonic skin/hair phenotype is itself considered strong diagnostic support even before cardiac criteria are fully met.

Genetic testing: - Recommended approach: Targeted single-gene sequencing of JUP (particularly for the 2157del2 founder variant in patients from/with ancestry linked to endemic regions), or inclusion of JUP and DSP within an ARVC/cardiomyopathy gene panel (alongside PKP2, DSG2, DSC2, TMEM43, RYR2, LMNA, etc., for differential diagnosis of non-syndromic ARVC and other overlapping cardiomyopathies). - Whole-exome/whole-genome sequencing: Useful when panel testing is non-diagnostic, or in atypical/non-founder-population presentations (as demonstrated by the JUP-negative Arab-family case, PMID: 15494820), to identify novel/alternative loci. - Family cascade testing: Critical given autosomal recessive inheritance — testing sibs of an affected proband, and carrier testing of relatives in endemic populations, is a key secondary-prevention/counseling tool. - Prenatal/preimplantation testing: Feasible once a family's causal variant is known, though this was not specifically discussed in the sources reviewed.

Differential diagnosis: Non-syndromic ARVC (PKP2, DSG2, DSC2, TMEM43-related), Carvajal syndrome (DSP-related, LV-predominant), other ectodermal dysplasias/keratoderma syndromes with cardiac involvement (e.g., Bass syndrome, cardiofaciocutaneous overlap conditions), and other causes of woolly hair (e.g., isolated hereditary woolly hair, Noonan-syndrome-associated woolly hair).

Screening: Given the founder-mutation, high-prevalence context, targeted carrier/genetic screening in the Naxos/endemic population, and cardiac screening (ECG/echo) of homozygous or at-risk family members beginning in childhood/pre-adolescence are recommended surveillance strategies, given the high cardiac penetrance and sudden-death risk once the concealed phase transitions to overt disease.

11. Outcome/Prognosis

• Mortality: From the seminal natural-history literature (Protonotarios/Tsatsopoulou cohort, summarized PMID: 16722579): annual disease-related mortality ~3%, with annual sudden cardiac death mortality ~2.3% — figures that place Naxos disease among the more malignant arrhythmogenic cardiomyopathies.
• Sudden death as first presentation: Documented — sudden cardiac death can be the initial clinical manifestation of previously "concealed"-phase disease, particularly in the context of exertion, underscoring the importance of pre-symptomatic screening in known carriers/homozygotes.
• Risk stratification factors: History of syncope, symptomatic arrhythmia, severe/extensive right ventricular disease developing before age 35, and left ventricular involvement are identified as adverse prognostic markers (PMID: 16722579).
• Disease course/complications: Progressive biventricular structural involvement occurs in >50% of patients over a 10-year follow-up; end-stage right (or biventricular) heart failure can necessitate heart transplantation.
• Carvajal (DSP) variant prognosis: Notably worse and earlier — approximately 50% develop heart failure, with death commonly occurring in childhood or adolescence, reflecting the more aggressive, left-ventricle-predominant dilated-cardiomyopathy phenotype of this allelic variant (genotype-outcome study, PMC11924745).
• Functional/QoL outcomes: Beyond mortality, morbidity includes activity restriction, psychological burden of living with ICD/sudden-death risk, and the chronic dermatologic discomfort of PPK (fissuring, pain), though dedicated disease-specific QoL instrument data were not identified.
• Prognostic biomarkers: No blood-based prognostic biomarker specific to Naxos disease was identified; risk stratification remains primarily clinical/imaging/electrophysiological, as in ARVC generally.

12. Treatment

There is no curative or disease-modifying therapy that reverses desmosomal dysfunction or established fibrofatty replacement in Naxos disease; management is centered on arrhythmia/sudden-death prevention and heart-failure supportive care, with emerging mechanism-targeted investigational approaches.

Pharmacotherapy (arrhythmia management): - Antiarrhythmic drugs — sotalol and amiodarone, alone or combined with β-blockers, used for suppression of sustained ventricular tachycardia (PMID: 16722579). Suggested MAXO term: MAXO:0000647-adjacent pharmacotherapy action, more precisely treatment_term NCIT:C15986 (Pharmacotherapy) with therapeutic_agent CHEBI entries for sotalol/amiodarone. - β-blockers: Standard adjunct for arrhythmia suppression and heart-failure management. - Heart-failure pharmacotherapy: Diuretics and ACE inhibitors for right (or biventricular) heart failure symptoms in advanced disease (PMID: 16722579); by extension, standard contemporary guideline-directed medical therapy (including possibly ARBs/mineralocorticoid antagonists) would be applied, though Naxos-specific trial data are lacking.

Device therapy (primary/secondary prevention of sudden death): - Implantable cardioverter-defibrillator (ICD): The cornerstone of sudden-death prevention — recommended for primary prevention in symptomatic patients or those with significant structural disease progression, generally before age 35 in the Naxos cohort data reviewed (PMID: 16722579), and for secondary prevention after aborted cardiac arrest or sustained VT, consistent with general ARVC ICD guidelines (e.g., PMID: 30678832 on primary-prevention ICD outcomes in ARVC). Suggested MAXO term: relates to MAXO:0000004-adjacent device implantation procedures (device/surgical action); therapeutic_modality DEVICE. - Catheter ablation (endocardial/epicardial, electroanatomic mapping-guided): Used for control of recurrent VT refractory to antiarrhythmic drugs, reducing arrhythmic burden and ICD shocks, though it does not eliminate sudden-death risk and is typically adjunctive to ICD therapy.

Surgical/advanced: - Heart transplantation: Reserved for end-stage refractory heart failure (right- or biventricular) (PMID: 16722579); relevant MAXO term MAXO:0010039 (organ transplantation).

Behavioral/lifestyle: - Exercise restriction: A central, non-pharmacologic recommendation — avoidance of competitive/endurance exercise to reduce mechanical stress on the desmosomally weakened myocardium and lower arrhythmic/progression risk, extrapolated from general ARVC guidance and supported mechanistically by exercise-accelerated disease in Jup+/− mouse models. Relevant MAXO term: behavioral counseling MAXO:0000077. - Dermatologic supportive care: Emollients, keratolytics, and mechanical offloading for palmoplantar keratoderma; standard dermatologic management, not curative.

Genetic counseling: Given autosomal recessive inheritance, family/genetic counseling for at-risk relatives and reproductive planning is an important component of comprehensive care (MAXO:0000079).

Experimental/targeted therapy: - GSK3β inhibition — mechanistically supported by murine model data (Chelko/Judge, PMID: 27170944) as a pathway-targeted approach to arrhythmogenic (desmosomal) cardiomyopathy broadly (not JUP-Naxos-specific in isolation but directly relevant given the shared mechanism). This has progressed to an active human trial: "Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy" (ClinicalTrials.gov NCT06174220), representing the most disease-mechanism-proximal experimental therapeutic under active clinical investigation for this disease class. - No gene therapy, gene editing, RNA-based (ASO/siRNA), or cell-therapy approach specific to JUP-Naxos disease was identified as being in active clinical development in the sources reviewed, though desmosomal-gene replacement/correction strategies are an area of broader preclinical ARVC research interest.

Treatment algorithm summary: Risk-stratify (syncope/VT history, RV/LV extent of disease, age) → ICD for primary/secondary prevention in higher-risk patients → antiarrhythmics (sotalol/amiodarone ± β-blocker) for arrhythmia suppression and ICD-shock reduction → ablation for refractory VT → heart-failure GDMT as ventricular function declines → transplantation for end-stage disease → lifelong exercise restriction and family cascade screening/counseling throughout.

13. Prevention

• Primary prevention: Not possible in the genetic sense (cannot prevent inheritance of a homozygous recessive genotype), but exercise restriction in genotype-positive/at-risk individuals functions as a primary preventive measure against triggering or accelerating cardiac disease expression and arrhythmic events.
• Secondary prevention (early detection): Cardiac screening (ECG, echocardiography, and where available cardiac MRI) of relatives of an affected proband — particularly siblings and other homozygous or genetically confirmed at-risk family members — beginning in childhood/early adolescence, to detect the transition from concealed to overt disease before a sudden-death event occurs. Population-level carrier/genetic screening is of particular relevance in the endemic Naxos/Aegean population given the high (~5%) carrier frequency.
• Tertiary prevention: ICD implantation, antiarrhythmic therapy, and heart-failure management (as above) to prevent sudden death and slow functional decline once disease is established.
• Genetic counseling: For carrier couples (both from endemic or consanguineous backgrounds) regarding recurrence risk (25% for offspring of two carriers), and for confirmed homozygous individuals regarding their own risk and that of their children (obligate carriers, or affected if partner is also a carrier).
• Immunization: Not applicable (non-infectious disease).
• Public health: No organized public-health screening program specific to Naxos disease was identified in this search; management is family/genetic-counseling based rather than population-wide.
• Prophylaxis: No pharmacologic prophylaxis is established to prevent onset of the cardiac phenotype in genotype-positive individuals; management is surveillance- and arrhythmia-prevention—based once disease is diagnosed or strongly anticipated.

14. Other Species / Natural Disease

• Taxonomy: No naturally occurring veterinary/companion-animal analog of Naxos disease (JUP-associated cardiocutaneous syndrome) was identified in this search — unlike some other Mendelian disorders, this does not appear to have a well-characterized spontaneous animal counterpart in OMIA-type registries based on the sources reviewed.
• Orthologous gene: Jup is highly conserved; mouse Jup (NCBI Gene, chr11 in mouse) and other vertebrate orthologs are used extensively in laboratory models (see Section 15) rather than representing naturally occurring disease.
• Comparative biology: The desmosome/plakoglobin structural and Wnt-signaling roles are deeply conserved across vertebrates, which underlies the strong translational relevance of the mouse and zebrafish models described below, despite the absence of documented natural veterinary disease.
• Zoonotic potential/transmission: Not applicable — purely genetic, non-transmissible disease.

15. Model Organisms

Mouse models (most extensively characterized; summarized in the 2020 review "Genetic Animal Models for Arrhythmogenic Cardiomyopathy," PMID: 32670084): - Global Jup knockout: Complete Jup deficiency is embryonic lethal, with severe cardiac defects and markedly reduced cardiac desmosomes (classic Kemler/Birchmeier-era developmental studies, 1996), demonstrating an essential developmental role for plakoglobin beyond the postnatal disease phenotype. - Heterozygous global Jup knockout (Jup+/−): Develop right ventricular dilation, ventricular arrhythmia, and decreased RV function without gross structural malformation; disease is exercise-inducible/accelerated — 8 weeks of swim training produced increased RV dilation evident by 6 months, directly modeling the human exercise-as-modifier phenomenon (Kirchhof et al., referenced in PMC7327121). - Cardiac-specific / inducible cardiac-specific plakoglobin-deficient mice: Exhibit severe cardiac fibrosis, contractile dysfunction, ventricular arrhythmia, and dilation, supporting a loss-of-function disease mechanism localized to the heart. - Cardiac-specific transgenic overexpression of mutant (Naxos-type truncated) or even wild-type plakoglobin (Myh6 promoter): causes increased mortality*, indicating that excess/dysregulated plakoglobin expression is independently toxic — informative for understanding dosage sensitivity. - Jup-c.2037-2038del knock-in mice (Chen lab): precisely models the human founder mutation. Straight knock-in mice die shortly after birth due to nonsense-mediated mRNA decay (NMD) of the mutant transcript; when introns 10–14 were deleted to block NMD and rescue truncated-protein expression, mice were protected from the ACM phenotype — strong genetic proof that loss of truncated protein expression (via NMD), not merely haploinsufficiency, underlies severity, and that restoring even truncated protein is protective — an important mechanistic and potential therapeutic-strategy insight (e.g., for NMD-modulating or exon-skipping-type approaches). - Two-model convergence study (Chelko/Judge, JCI Insight, PMID: 27170944): Combined a transgenic plakoglobin-Naxos-mutant model and a Dsg2 knock-in model, showing shared structural, histopathological, and arrhythmic phenotypes, and demonstrating that GSK3β inhibition (SB216763)* rescues myocyte injury, fibrosis/inflammation, and ventricular ectopy across both models — directly nominating GSK3β as a convergent, druggable node and providing the preclinical basis for the ongoing human GSK3-inhibitor trial (NCT06174220).

Zebrafish models: - Morpholino jup knockdown: Produces cardiac edema, decreased heart size, and blood reflux between chambers, with altered desmosomal ultrastructure — useful for rapid, scalable developmental/structural phenotyping, though the two-chambered, regenerative zebrafish heart limits modeling of RV-specific adult disease.

Model recapitulation and limitations: - Recapitulated: ventricular arrhythmia, RV (and with cardiac-specific loss, more global) dilation and dysfunction, fibrosis, intercalated-disc/connexin-43 mislocalization, exercise-induced disease acceleration. - Not recapitulated: Fibro-fatty (adipocytic) replacement — the histologic hallmark of human ARVC/Naxos disease — is not reproduced in mouse or zebrafish models, a major translational gap. Mice frequently require homozygous/biallelic manipulation to approximate phenotypes that in some human desmosomal genes (e.g., dominant PKP2 ARVC) arise from heterozygous mutations, reflecting species differences in dosage sensitivity. The cutaneous (woolly hair/PPK) component of the human syndrome is generally not the focus of these cardiac-oriented models. - Applications: These models have been central to establishing loss-of-function as the operative mechanism, identifying GSK3β/Wnt signaling as a therapeutic target, characterizing exercise as a disease accelerant, and are now supporting translational pharmacologic (GSK3 inhibitor) development.

Resources: MGI (Mouse Genome Informatics) for Jup knockout/knock-in alleles; ZFIN for zebrafish jup morpholino/mutant lines; IMPC/KOMP repositories for additional conditional allele resources.

Summary of Key PMIDs Cited

Note on evidence quality/gaps for KB curation: Most quantitative figures (prevalence ~1:1000, carrier rate ~5%, annual mortality ~3%/SCD ~2.3%) trace back to the same core Protonotarios/Tsatsopoulou clinical cohort literature and its review syntheses; independent replication in non-Greek cohorts is limited given global rarity. The GSK3β/Wnt mechanism, while compelling and directly relevant, is derived from desmosomal ARVC models broadly (plakoglobin-Naxos-mutant and Dsg2 models) rather than exclusively JUP-Naxos-specific systems, and should be flagged with evidence_source: MODEL_ORGANISM when curated. Direct exact-quote abstract snippets should be re-verified against PubMed/PMC full text at curation time per dismech's anti-hallucination SOP before being entered as evidence items.

Sources: - Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease) - PubMed - Naxos disease: Cardiocutaneous syndrome due to cell adhesion defect - PMC - Naxos disease in an Arab family is not caused by the Pk2157del2 mutation - PubMed - Naxos disease and Carvajal syndrome: cardiocutaneous disorders... - PubMed - Genotype and cardiac outcome in patients with cardiocutaneous syndrome (Naxos disease variant: Carvajal syndrome) - PMC - A novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular cardiomyopathy - PubMed - Central role for GSK3β in the pathogenesis of arrhythmogenic cardiomyopathy - PubMed - Genetic Animal Models for Arrhythmogenic Cardiomyopathy - PMC - Naxos Disease and Related Cardio-Cutaneous Syndromes - PMC - Entry - #601214 - NAXOS DISEASE; NXD - OMIM - Entry - *173325 - JUNCTION PLAKOGLOBIN; JUP - OMIM - Orphanet: Naxos disease - Naxos disease - National Organization for Rare Disorders / MONDO - Naxos Disease | GARD - NIH - Targeted Therapy With GSK-3 Inhibition for Arrhythmogenic Cardiomyopathy - ClinicalTrials.gov NCT06174220